Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 3

Sponsor Class

INDUSTRY 6OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 2NET 1Gastrointestinal 1Endocrine 1

Conditions

Pancreatic Neoplasms 1Neuroendocrine Tumors 1Neuroectodermal Tumors, Primitive 1Glioma 1Glioblastoma 1

Interventions

Cyclophosphamide 548pembrolizumab 385Radiotherapy 363Bevacizumab 360Carboplatin 351Rituximab 315Cisplatin 300Gemcitabine 297Paclitaxel 288Dexamethasone 272Docetaxel 271fludarabine phosphate 241Doxorubicin 231Nivolumab 220Etoposide 209Cytarabine 203Lenalidomide 201fludarabine 191Oxaliplatin 191Fluorouracil 190Melphalan 189Filgrastim 188Capecitabine 175Calcium Dobesilate 172Radiosurgery 167Erlotinib Hydrochloride 167Methotrexate 163Bortezomib 162Granulocyte Colony-Stimulating Factor 154Whole-Body Irradiation 144

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Has results × TH 302 × Clear all
NCT02402062 2020-07-27

A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours

Grupo Espanol de Tumores Neuroendocrinos

Phase 2 Completed
17 enrolled 55 charts
EndocrineGastrointestinalNET

Pancreatic Neoplasms, Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors

NCT02342379 2020-04-10

TH-302 in Combination With Bevacizumab for Glioblastoma

The University of Texas Health Science Center at San Antonio

Phase 2 Completed
35 enrolled 6 charts
CNS

Glioblastoma

NCT01403610 2019-07-24

Safety and Efficacy Study of TH-302 CNS Penetration in Recurrent High Grade Astrocytoma Following Bevacizumab

The University of Texas Health Science Center at San Antonio

Phase 2 Completed
28 enrolled 9 charts
CNS

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡